Odi Pharma Polska Sp. z o.o. (Poland)

Main Activities: Pharmaceutical Preparation Manufacturing

Secondary Activities: All Other Food Manufacturing | Toilet Preparation Manufacturing | General Line Grocery Merchant Wholesalers | Other Miscellaneous Nondurable Goods Merchant Wholesalers | Department Stores | All Other Nondepository Credit Intermediation | All Other Professional, Scientific, and Technical Services | Convention and Trade Show Organizers

Full name: Odi Pharma Polska Sp. z o.o.

Profile Updated: June 05, 2025

Odi Pharma Polska Sp. z o.o. is an enterprise located in Poland, with the main office in Warsaw. The company operates in the Pharmaceutical Preparation Manufacturing industry. It was established on April 26, 2018. The company’s latest financial report indicates a net sales revenue drop of 86.45% in 2025. A negative growth of 82.65% was recorded in its total assets.

Headquarters
Ul. Towarowa 28
Warsaw; Mazowieckie; Postal Code: 00-839

Contact Details: Purchase the Odi Pharma Polska Sp. z o.o. report to view the information.

Basic Information

Registered Capital:

Purchase the Odi Pharma Polska Sp. z o.o. report to view the information.

Financial Auditors:

Purchase the Odi Pharma Polska Sp. z o.o. report to view the information.

Incorporation Date:

April 26, 2018

Key Executives

Purchase this report to view the information.

Management Board Member

Ownership Details

Purchase this report to view the information.

100%

Company Performance

Financial values in the chart are available after Odi Pharma Polska Sp. z o.o. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.

Net sales revenue

-86.45%▼

Total operating revenue

-86.37%▼

Operating profit (EBIT)

N/A

EBITDA

N/A

Net Profit (Loss) for the Period

N/A

Total Assets

-82.65%▼

Total Equity

-98.88%▼

Operating Profit Margin (ROS)

N/A

Net Profit Margin

N/A

Return on Equity (ROE)

N/A

Similar companies